全球及中国甜菊糖甜味剂市场深度分析及需求预测报告2025-2031年 本文源自：中赢信合研究网 1 甜菊糖甜味剂市场概述 1.1 甜菊糖甜味剂行业概述及统计范围 1.2 按照不同产品类型，甜菊糖甜味剂主要可以分为如下几个类别 1.2.1 不同产品类型甜菊糖甜味剂增长趋势2019 VS 2025 VS 2031 1.2.2 Reb-A甜菊糖 1.2.3 STV甜菊糖 1.2.4 葡萄糖基甜菊糖 1.2.5 Reb-M甜菊糖 1.2.6 Reb-D甜菊糖 1.3 从不同应用，甜菊糖甜味剂主要包括如下几个方面 1.3.1 不同应用甜菊糖甜味剂增长趋势2019 VS 2025 VS 2031 9.3.4 Julong High-tech公司简介及主要业务 9.3.5 Julong High-tech企业最新动态 9.4 Biolotus Technology 9.4.1 Biolotus Technology基本信息、甜菊糖甜味剂生产基地、销售区域、竞争对手及市场地位 9.4.2 Biolotus Technology甜菊糖甜味剂产品规格、参数及市场应用 9.4.3 Biolotus Technology甜菊糖甜味剂 ...

Investment Rating - The investment rating for the company is "Buy" with a maintained rating for the next six months [6][17]. Core Views - The approval of D-Allulose as a food ingredient marks a significant milestone for the company, positioning it as the second enterprise in China to receive approval for enzyme-based production of D-Allulose, enhancing its competitive edge in the functional sweetener market [3][4]. - The company currently has an annual production capacity of 10,000 tons for D-Allulose and is evaluating the potential for further expansion, indicating a strong growth trajectory in the sweetener segment [3][4]. - The financial projections for the company show a recovery in net profit, with expected figures of 1.17 billion, 2.12 billion, and 2.37 billion yuan for 2025, 2026, and 2027 respectively, reflecting a significant growth rate [4][3]. Summary by Sections Company Overview - The company is recognized for its technological leadership in the functional sweetener sector, particularly with the recent approval of its enzyme product for D-Allulose production [3]. Financial Performance - The projected revenue for 2025 is 6.63 billion yuan, with a growth rate of 25.03% compared to the previous year [4]. - The expected EBITDA for 2025 is 1.83 billion yuan, indicating a strong operational performance [4]. - The net profit for 2025 is projected to be 1.17 billion yuan, with a remarkable growth rate of 110.40% [4]. Market Position - The approval of D-Allulose aligns the company with international standards, as it follows similar approvals in the US, Canada, Australia, and New Zealand, suggesting a robust market potential both domestically and internationally [2][3].